Click on to discover how VIZZ works, its benefits, what presbyopia is, and why it could be a game-changer for millions.
The Food and Drug Administration has approved VIZZ, an aceclidine-based eye drop designed for adults with presbyopia. This marks the first treatment of its kind to offer effective near-vision relief without impacting distance vision significantly.
VIZZ gently shrinks the pupil, creating a “pinhole effect” that sharpens nearby objects while sparing the eye’s focusing muscles. This allows clear near vision for up to 10 hours after a single daily dose.
Pharmaceutical company LENZ developed VIZZ, aiming to improve the lives of millions of people experiencing blurry near vision. CEO Eef Schimmelpennink called the approval a transformative milestone for presbyopia treatment options.
Three randomized, double-masked, controlled Phase II trials tested VIZZ, involving hundreds of participants. Across 30,000-plus treatment days, the drops were well tolerated, with no serious adverse events reported.
VIZZ begins improving near vision shortly after administration. Users notice a difference quickly, making it a practical solution for daily routines without relying on reading glasses.
One drop in the morning can provide clear near vision for up to 10 hours. This allows uninterrupted reading, phone use, or other close-up tasks without the need for glasses.
Unlike older treatments such as Vuity, VIZZ avoids overstimulating the eye’s ciliary muscles. This reduces the risk of side effects like brow heaviness, blurred distance vision, or rare retinal issues.
Participants in clinical trials reported minimal discomfort and significant improvement in reading and other close-up activities. Many found the drops preferable to carrying multiple pairs of reading glasses.
VIZZ is expected to be widely available in the fourth quarter of 2025, giving millions of people access to the first FDA-approved aceclidine-based treatment for presbyopia.
This approval offers a new, convenient option for adults struggling with presbyopia. Eye care professionals may now have a reliable, non-invasive solution to meet the needs of patients seeking freedom from reading glasses.
Presbyopia is the gradual loss of your eyes’ ability to focus on nearby objects. It typically begins in your early to mid-40s and worsens until around age 65, affecting daily activities like reading or using smartphones.
Holding books or devices at arm’s length, blurred vision at normal reading distance, or eyestrain after close-up work are common early indicators of presbyopia.
Simple tasks such as reading food labels, working on a computer, or crafting can become difficult. Presbyopia slowly reduces independence in near-vision activities without corrective measures.
If blurry near vision interferes with daily life, schedule an eye exam. Immediate care is needed if sudden vision changes, flashes of light, or double vision occur.
The eye relies on the cornea and lens to focus light. With age, the lens hardens and loses flexibility, making it difficult to focus on close objects, resulting in blurry near vision.
Lens and muscle function
The lens changes shape to focus, aided by a surrounding circular muscle. As the lens stiffens with age, this system can no longer adjust sufficiently for near vision.
Age is the greatest risk factor. Other contributors include farsightedness, diabetes, cardiovascular conditions, multiple sclerosis, or medications such as antihistamines and antidepressants.
Common symptoms
Blurred near vision, eyestrain, headaches after reading, and difficulty in dim lighting are typical signs. Recognizing these early helps manage presbyopia effectively.
A basic eye exam can confirm presbyopia. Tests assess the ability to focus on close objects and determine the most suitable corrective options.
Reading glasses or bifocals remain common remedies. They provide immediate near-vision correction but require carrying multiple pairs or switching lenses for different tasks.
Contact lenses
Multifocal or monovision contact lenses can correct presbyopia. They offer convenience for some users, but may take time to adjust to and don’t suit everyone.
Surgical options
Procedures like corneal inlays or lens replacement surgery are alternatives. These options are more invasive and may involve higher costs or potential risks.
Good lighting, regular eye exams, and ergonomic adjustments at work can ease presbyopia’s daily impact. Early awareness helps reduce eye strain and fatigue.
Presbyopia worsens gradually over time. Vision may become noticeably poorer between ages 40 and 50, often stabilizing around age 65.
While presbyopia can’t be prevented, protecting eyes from UV light, managing chronic diseases, and regular checkups help maintain overall eye health.
Some people use both glasses and drops or surgery. Combining approaches allows flexibility based on lifestyle needs and vision goals.
Presbyopia affects an estimated 1.8 billion people worldwide. Awareness campaigns in various countries highlight the importance of eye exams and accessible treatments to maintain quality of life.
Patient education
Understanding presbyopia helps patients make informed choices about corrective options, whether glasses, contacts, drops like VIZZ, or surgery. Awareness also promotes early intervention.
Future treatments
New therapies like VIZZ hint at a growing focus on non-invasive, pupil-selective treatments for presbyopia. Future innovations may further improve near vision with fewer side effects.
